Relay Therapeutics (RLAY) Net Equity Issued and Repurchased (2019 - 2024)

Relay Therapeutics (RLAY) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $218.2 million in Q3 2024.

• On a quarterly basis, Net Equity Issued and Repurchased rose 2221.28% year-over-year to $218.2 million in Q3 2024; TTM through Sep 2024 was $530.2 million, a 79.22% increase from a year earlier, with the FY2024 full-year figure at $17.9 million, down 40.92% from the prior year.
• Net Equity Issued and Repurchased for Q3 2024 stood at $218.2 million, up from $17.9 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for RLAY reached as high as $284.7 million in Q3 2022 and fell as low as $56000.0 in Q4 2020.
• Historically, Net Equity Issued and Repurchased has averaged $38.4 million across 5 years, with a median of $892500.0 in 2021.
• Across the five-year window, Net Equity Issued and Repurchased soared 31463.19% in 2022 and tumbled 96.7% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $56000.0 in 2020, then surged by 1080.36% to $661000.0 in 2021, then jumped by 42971.1% to $284.7 million in 2022, then plunged by 96.7% to $9.4 million in 2023, then surged by 2221.28% to $218.2 million in 2024.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $218.2 million in Q3 2024, $17.9 million in Q1 2024, and $9.4 million in Q3 2023.